Loading…
“MIATA”—Minimal Information about T Cell Assays
Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of...
Saved in:
| Published in: | Immunity (Cambridge, Mass.) Mass.), 2009-10, Vol.31 (4), p.527-528 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93 |
| container_end_page | 528 |
| container_issue | 4 |
| container_start_page | 527 |
| container_title | Immunity (Cambridge, Mass.) |
| container_volume | 31 |
| creator | Janetzki, Sylvia Britten, Cedrik M. Kalos, Michael Levitsky, Hyam I. Maecker, Holden T. Melief, Cornelius J.M. Old, Lloyd J. Romero, Pedro Hoos, Axel Davis, Mark M. |
| description | Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem. |
| doi_str_mv | 10.1016/j.immuni.2009.09.007 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3762500</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1074761309004191</els_id><sourcerecordid>3236881571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93</originalsourceid><addsrcrecordid>eNp9UdFq2zAUFaNl7bL9QRmGwt6cXkm2ZL8MQljXQEtfsmchy_KqYEuZZAfylo_oY_tz-ZLKJLTbHgoX7gWdc-49OghdYJhiwOxqNTVdN1gzJQDldCzgH9A5hpKnGS7gZJx5lnKG6Rn6FMIKAGd5CR_RGS4LSqGAc5Tvd093i9lytt8973ePd8aaTrbJwjbOd7I3ziayckOfLJO5bttkFoLchs_otJFt0F-OfYJ-Xf9Yzm_S2_ufi_nsNlVZUfZpoWhBGoCGUs5UhWkuK6gq4FLLuiY4r4FmRCnFNK9rRnAJTU5LTiKLal3SCfp-0F0PVadrpW3vZSvWPh7pt8JJI_59seZB_HYbEfeRHCAKfDsKePdn0KEXnQkqGpFWuyEIxlnBMSMRePkfcOUGb6M5gXPICONZPsplB5TyLgSvm9dTMIgxFbESh1TEmIoYC3ikff3bxhvpGMObTx0_c2O0F0EZbZWujdeqF7Uz7294AQMjocE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504267450</pqid></control><display><type>article</type><title>“MIATA”—Minimal Information about T Cell Assays</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Janetzki, Sylvia ; Britten, Cedrik M. ; Kalos, Michael ; Levitsky, Hyam I. ; Maecker, Holden T. ; Melief, Cornelius J.M. ; Old, Lloyd J. ; Romero, Pedro ; Hoos, Axel ; Davis, Mark M.</creator><creatorcontrib>Janetzki, Sylvia ; Britten, Cedrik M. ; Kalos, Michael ; Levitsky, Hyam I. ; Maecker, Holden T. ; Melief, Cornelius J.M. ; Old, Lloyd J. ; Romero, Pedro ; Hoos, Axel ; Davis, Mark M.</creatorcontrib><description>Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.</description><identifier>ISSN: 1074-7613</identifier><identifier>EISSN: 1097-4180</identifier><identifier>DOI: 10.1016/j.immuni.2009.09.007</identifier><identifier>PMID: 19833080</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Clinical trials ; Gene expression ; Humans ; Immunoassay ; Immunoassay - standards ; Immunotherapy ; Laboratories ; Lymphocytes ; Meetings ; Monitoring, Immunologic - standards ; Neoplasms - therapy ; Peptides ; Practice Guidelines as Topic - standards ; Quality standards ; Reporting requirements ; Stock rights ; T-Lymphocytes - immunology ; Viral Vaccines - immunology ; Viral Vaccines - therapeutic use ; Virus Diseases - therapy</subject><ispartof>Immunity (Cambridge, Mass.), 2009-10, Vol.31 (4), p.527-528</ispartof><rights>2009 Elsevier Inc.</rights><rights>Copyright Elsevier Limited Oct 16, 2009</rights><rights>2009 Elsevier Inc. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93</citedby><cites>FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19833080$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Janetzki, Sylvia</creatorcontrib><creatorcontrib>Britten, Cedrik M.</creatorcontrib><creatorcontrib>Kalos, Michael</creatorcontrib><creatorcontrib>Levitsky, Hyam I.</creatorcontrib><creatorcontrib>Maecker, Holden T.</creatorcontrib><creatorcontrib>Melief, Cornelius J.M.</creatorcontrib><creatorcontrib>Old, Lloyd J.</creatorcontrib><creatorcontrib>Romero, Pedro</creatorcontrib><creatorcontrib>Hoos, Axel</creatorcontrib><creatorcontrib>Davis, Mark M.</creatorcontrib><title>“MIATA”—Minimal Information about T Cell Assays</title><title>Immunity (Cambridge, Mass.)</title><addtitle>Immunity</addtitle><description>Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.</description><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Clinical trials</subject><subject>Gene expression</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Immunoassay - standards</subject><subject>Immunotherapy</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Meetings</subject><subject>Monitoring, Immunologic - standards</subject><subject>Neoplasms - therapy</subject><subject>Peptides</subject><subject>Practice Guidelines as Topic - standards</subject><subject>Quality standards</subject><subject>Reporting requirements</subject><subject>Stock rights</subject><subject>T-Lymphocytes - immunology</subject><subject>Viral Vaccines - immunology</subject><subject>Viral Vaccines - therapeutic use</subject><subject>Virus Diseases - therapy</subject><issn>1074-7613</issn><issn>1097-4180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9UdFq2zAUFaNl7bL9QRmGwt6cXkm2ZL8MQljXQEtfsmchy_KqYEuZZAfylo_oY_tz-ZLKJLTbHgoX7gWdc-49OghdYJhiwOxqNTVdN1gzJQDldCzgH9A5hpKnGS7gZJx5lnKG6Rn6FMIKAGd5CR_RGS4LSqGAc5Tvd093i9lytt8973ePd8aaTrbJwjbOd7I3ziayckOfLJO5bttkFoLchs_otJFt0F-OfYJ-Xf9Yzm_S2_ufi_nsNlVZUfZpoWhBGoCGUs5UhWkuK6gq4FLLuiY4r4FmRCnFNK9rRnAJTU5LTiKLal3SCfp-0F0PVadrpW3vZSvWPh7pt8JJI_59seZB_HYbEfeRHCAKfDsKePdn0KEXnQkqGpFWuyEIxlnBMSMRePkfcOUGb6M5gXPICONZPsplB5TyLgSvm9dTMIgxFbESh1TEmIoYC3ikff3bxhvpGMObTx0_c2O0F0EZbZWujdeqF7Uz7294AQMjocE</recordid><startdate>20091016</startdate><enddate>20091016</enddate><creator>Janetzki, Sylvia</creator><creator>Britten, Cedrik M.</creator><creator>Kalos, Michael</creator><creator>Levitsky, Hyam I.</creator><creator>Maecker, Holden T.</creator><creator>Melief, Cornelius J.M.</creator><creator>Old, Lloyd J.</creator><creator>Romero, Pedro</creator><creator>Hoos, Axel</creator><creator>Davis, Mark M.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20091016</creationdate><title>“MIATA”—Minimal Information about T Cell Assays</title><author>Janetzki, Sylvia ; Britten, Cedrik M. ; Kalos, Michael ; Levitsky, Hyam I. ; Maecker, Holden T. ; Melief, Cornelius J.M. ; Old, Lloyd J. ; Romero, Pedro ; Hoos, Axel ; Davis, Mark M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Clinical trials</topic><topic>Gene expression</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Immunoassay - standards</topic><topic>Immunotherapy</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Meetings</topic><topic>Monitoring, Immunologic - standards</topic><topic>Neoplasms - therapy</topic><topic>Peptides</topic><topic>Practice Guidelines as Topic - standards</topic><topic>Quality standards</topic><topic>Reporting requirements</topic><topic>Stock rights</topic><topic>T-Lymphocytes - immunology</topic><topic>Viral Vaccines - immunology</topic><topic>Viral Vaccines - therapeutic use</topic><topic>Virus Diseases - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Janetzki, Sylvia</creatorcontrib><creatorcontrib>Britten, Cedrik M.</creatorcontrib><creatorcontrib>Kalos, Michael</creatorcontrib><creatorcontrib>Levitsky, Hyam I.</creatorcontrib><creatorcontrib>Maecker, Holden T.</creatorcontrib><creatorcontrib>Melief, Cornelius J.M.</creatorcontrib><creatorcontrib>Old, Lloyd J.</creatorcontrib><creatorcontrib>Romero, Pedro</creatorcontrib><creatorcontrib>Hoos, Axel</creatorcontrib><creatorcontrib>Davis, Mark M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunity (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Janetzki, Sylvia</au><au>Britten, Cedrik M.</au><au>Kalos, Michael</au><au>Levitsky, Hyam I.</au><au>Maecker, Holden T.</au><au>Melief, Cornelius J.M.</au><au>Old, Lloyd J.</au><au>Romero, Pedro</au><au>Hoos, Axel</au><au>Davis, Mark M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>“MIATA”—Minimal Information about T Cell Assays</atitle><jtitle>Immunity (Cambridge, Mass.)</jtitle><addtitle>Immunity</addtitle><date>2009-10-16</date><risdate>2009</risdate><volume>31</volume><issue>4</issue><spage>527</spage><epage>528</epage><pages>527-528</pages><issn>1074-7613</issn><eissn>1097-4180</eissn><abstract>Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19833080</pmid><doi>10.1016/j.immuni.2009.09.007</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1074-7613 |
| ispartof | Immunity (Cambridge, Mass.), 2009-10, Vol.31 (4), p.527-528 |
| issn | 1074-7613 1097-4180 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3762500 |
| source | BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS |
| subjects | Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Clinical trials Gene expression Humans Immunoassay Immunoassay - standards Immunotherapy Laboratories Lymphocytes Meetings Monitoring, Immunologic - standards Neoplasms - therapy Peptides Practice Guidelines as Topic - standards Quality standards Reporting requirements Stock rights T-Lymphocytes - immunology Viral Vaccines - immunology Viral Vaccines - therapeutic use Virus Diseases - therapy |
| title | “MIATA”—Minimal Information about T Cell Assays |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A23%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%E2%80%9CMIATA%E2%80%9D%E2%80%94Minimal%20Information%20about%20T%20Cell%20Assays&rft.jtitle=Immunity%20(Cambridge,%20Mass.)&rft.au=Janetzki,%20Sylvia&rft.date=2009-10-16&rft.volume=31&rft.issue=4&rft.spage=527&rft.epage=528&rft.pages=527-528&rft.issn=1074-7613&rft.eissn=1097-4180&rft_id=info:doi/10.1016/j.immuni.2009.09.007&rft_dat=%3Cproquest_pubme%3E3236881571%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c489t-8c382f00f3376cb135ab0bb07aeadd215d0342ccc6e7dd62190f5397282f3ee93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504267450&rft_id=info:pmid/19833080&rfr_iscdi=true |